BRCA2 and soft tissue sarcoma: The patients with BRCA2 mutation (1x pancreas, 1x soft tissue sarcoma) received olaparib mono-therapy (plus pembrolizumab after 3 months in the case of soft tissue sarcoma) and continued treatment at time of data cut-off.